Background and Aims The incidence rate of hypertriglyceridemic pancreatitis (HTGP) has been continuously increasing in recent years, and there is no relevant guideline for its treatment available so far. Currently, the main treatment is conservative treatment based on lipid-lowering therapy, but the treatment efficacy is unsatisfactory, and the mortality and incidence rates of complications are still high, so the prognosis is relatively poor. Therefore, simple conservative treatment has some limitations. This study was conducted to evaluate the effectiveness and safety of pancreatic duct stent implantation in the treatment of HTGP, so as to provide a new approach for clinical management of this condition.Methods The clinical data of all patients with HTGP undergoing pancreatic duct stenting from January 2017 to July 2020 were reviewed, and the eligible patients were picked up according to the inclusion and exclusion criteria. In the included patients, the incidence of pancreatic ductal obstruction was observed; the APACHE II score, serum triglyceride (TG) level and blood glucose level were compared between admission and 48 h after treatment; the incidence of complications, mortality, incidence of new organ failure, the lengths of time for fasting and hospitalization as well as the hospitalization expenses were analyzed.Results A total of 33 patients were included, with 15 males and 18 females. Of the patients, the average age was (37.42±9.69) years, and the median serum TG level was 19.83 (11.85-39.18) mmol/L; 16 cases had pancreatic duct protein thrombus, and the incidence rates of pancreatic duct protein thrombus in cases with mild, moderate and severe HTGP were 17%, 56% and 100%, respectively. The severity of illness in patients with pancreatic duct protein thrombus was greater than those without pancreatic duct protein thrombus. Two patients (6%) developed post-ERCP hyperamylasemia, and postoperative complications occurred in 3 patients (9%). All patients were cured after pancreatic duct stenting. The median time of oral feeding was 3 (2-5) d, and the median length of hospital stay was 5 (3-9) d. After 48-h treatment, the APACHE II score decreased by approximately 70% compared with that at admission. In patients who underwent pancreatic duct stenting within 48 h after onset, the fasting time and hospitalization time were shortened by 33% and 38%, and the hospitalization cost was reduced by 33% compared with those undergoing pancreatic duct stenting over 48 h after onset, and all the differences had statistical significance (all P<0.05).Conclusion Early pancreatic duct stenting treatment can quickly alleviate the clinical symptoms of HTGP patients, significantly reduce the length of hospital stay and improve the prognosis. It is a safe and effective new treatment strategy.